gsk2857916
mAbexperimentalADC
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02064387)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Monomethylauristatin F
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2857916
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04398745 | Phase 1 | Jul 30, 2020 | GlaxoSmithKline |
| NCT04398680 | Phase 1 | Jul 30, 2020 | GlaxoSmithKline |
| NCT03848845 | Phase 2 | Mar 14, 2019 | GlaxoSmithKline, Merck |
| NCT03828292 | Phase 1 | Mar 14, 2019 | GlaxoSmithKline |
| NCT03715478 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2018 | GlaxoSmithKline, Myeloma Canada Research Network |
| NCT03544281 | Phase 2 | Aug 30, 2018 | GlaxoSmithKline, IQVIA |
| NCT03525678 | Phase 2 | Jun 18, 2018 | GlaxoSmithKline |
| NCT02064387 | Phase 1 | Jul 1, 2014 | GlaxoSmithKline |
| NCT03763370 | N/A | — | GlaxoSmithKline |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 8 | 3 | 2014 |
| IQVIA | For profit | 1 | 0 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| Myeloma Canada Research Network | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1